Open AccessRadioprotectors and Mitigators of Radiation‐Induced Normal Tissue Injury
Author(s) -
Citrin Deborah,
Cotrim Ana P.,
Hyodo Fuminori,
Baum Bruce J.,
Krishna Murali C.,
Mitchell James B.
Publication year - 2010
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2009-s104
Subject(s) - medicine , radiation therapy , radiation injury , cancer research , pharmacology , intensive care medicine
Radiation is used in the treatment of a broad range of malignancies. Exposure of normal tissue to radiation may result in both acute and chronic toxicities that can result in an inability to deliver the intended therapy, a range of symptoms, and a decrease in quality of life. Radioprotectors are compounds that are designed to reduce the damage in normal tissues caused by radiation. These compounds are often antioxidants and must be present before or at the time of radiation for effectiveness. Other agents, termed mitigators, may be used to minimize toxicity even after radiation has been delivered. Herein, we review agents in clinical use or in development as radioprotectors and mitigators of radiation‐induced normal tissue injury. Few agents are approved for clinical use, but many new compounds show promising results in preclinical testing.